Objectives 131I-MIBG is an active agent for treatment of patients with neuroendocrine tumors. The most common route of entry of a radioactive contamination into the body of a worker is by inhalation ...
Objectives This study involves radioimmunotherapy (RIT) with the human antibody L19SIP(Radretumab) labeled with 131I in combination with Whole Brain Radiation Treatment (WBRT). Our aim was to evaluate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback